Trial Profile
A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer; Squamous cell cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms NEOTALA
- Sponsors Pfizer
- 03 Oct 2023 Results published in the Oncologist
- 08 Jun 2021 Results of a biomarker analysis assessing tumor BRCA mutational status and zygosity and overall mutational landscape in patients treated with Talazoparib for whom biomarker results are available presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology